Abstract
25P Patient-reported outcomes (PROs) with coformulated vibostolimab/pembrolizumab (vibo/pembro) for metastatic cervical cancer (CC): Results from the KEYVIBE-005 study
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have